Editas Medicine, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $40.5M | $32.3M | $78.1M | $19.7M | $25.5M |
| Operating income | -$160.0M | -$251.2M | -$169.2M | -$225.9M | -$193.1M |
| Operating expenses | $200.5M | $283.5M | $247.3M | $245.7M | $218.7M |
| Cash from operations | -$165.2M | -$210.3M | -$132.2M | -$177.3M | -$163.8M |
| Capital expenditure | $607,000 | $8.8M | $4.7M | $4.1M | $8.0M |
| Free cash flow | -$165.8M | -$219.1M | -$136.9M | -$181.5M | -$171.8M |
| Impairments | $3.8M | $0 | $0 | $0 | $0 |
| Total assets | $186.5M | $341.6M | $499.2M | $514.3M | $677.5M |
| Total liabilities | $159.2M | $207.3M | $150.1M | $153.6M | $123.8M |
Shares outstanding 97.9M · Free float 95.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.